nodes	percent_of_prediction	percent_of_DWPC	metapath
Valproic Acid—SLC16A1—Methotrexate—lymphatic system cancer	0.144	0.217	CbGbCtD
Valproic Acid—CYP1A2—Carmustine—lymphatic system cancer	0.0783	0.118	CbGbCtD
Valproic Acid—SLC22A7—Methotrexate—lymphatic system cancer	0.0708	0.107	CbGbCtD
Valproic Acid—CYP3A5—Teniposide—lymphatic system cancer	0.0707	0.107	CbGbCtD
Valproic Acid—CYP2C19—Teniposide—lymphatic system cancer	0.057	0.0859	CbGbCtD
Valproic Acid—CYP2C9—Teniposide—lymphatic system cancer	0.0474	0.0714	CbGbCtD
Valproic Acid—SLC22A8—Methotrexate—lymphatic system cancer	0.0432	0.0651	CbGbCtD
Valproic Acid—CYP3A5—Vincristine—lymphatic system cancer	0.034	0.0513	CbGbCtD
Valproic Acid—SLC22A6—Methotrexate—lymphatic system cancer	0.0301	0.0454	CbGbCtD
Valproic Acid—CYP3A4—Cytarabine—lymphatic system cancer	0.028	0.0422	CbGbCtD
Valproic Acid—CYP3A4—Teniposide—lymphatic system cancer	0.0276	0.0415	CbGbCtD
Valproic Acid—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0193	0.0291	CbGbCtD
Valproic Acid—CYP3A4—Vincristine—lymphatic system cancer	0.0133	0.02	CbGbCtD
Valproic Acid—ALDH5A1—Vinblastine—Vincristine—lymphatic system cancer	0.00669	1	CbGdCrCtD
Valproic Acid—Neoplasm—Methotrexate—lymphatic system cancer	0.000414	0.00126	CcSEcCtD
Valproic Acid—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000414	0.00126	CcSEcCtD
Valproic Acid—Bladder pain—Methotrexate—lymphatic system cancer	0.000414	0.00126	CcSEcCtD
Valproic Acid—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000412	0.00125	CcSEcCtD
Valproic Acid—Alopecia—Mitoxantrone—lymphatic system cancer	0.000408	0.00124	CcSEcCtD
Valproic Acid—Confusional state—Bleomycin—lymphatic system cancer	0.000407	0.00124	CcSEcCtD
Valproic Acid—Vision blurred—Carmustine—lymphatic system cancer	0.000407	0.00124	CcSEcCtD
Valproic Acid—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000406	0.00123	CcSEcCtD
Valproic Acid—Tremor—Carmustine—lymphatic system cancer	0.000405	0.00123	CcSEcCtD
Valproic Acid—Oedema—Bleomycin—lymphatic system cancer	0.000404	0.00123	CcSEcCtD
Valproic Acid—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000404	0.00123	CcSEcCtD
Valproic Acid—Infection—Bleomycin—lymphatic system cancer	0.000401	0.00122	CcSEcCtD
Valproic Acid—Anaemia—Carmustine—lymphatic system cancer	0.000399	0.00121	CcSEcCtD
Valproic Acid—Back pain—Vincristine—lymphatic system cancer	0.000399	0.00121	CcSEcCtD
Valproic Acid—Vomiting—Teniposide—lymphatic system cancer	0.000399	0.00121	CcSEcCtD
Valproic Acid—Agitation—Carmustine—lymphatic system cancer	0.000397	0.0012	CcSEcCtD
Valproic Acid—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000396	0.0012	CcSEcCtD
Valproic Acid—Asthenia—Fludarabine—lymphatic system cancer	0.000395	0.0012	CcSEcCtD
Valproic Acid—Rash—Teniposide—lymphatic system cancer	0.000395	0.0012	CcSEcCtD
Valproic Acid—Dermatitis—Teniposide—lymphatic system cancer	0.000395	0.0012	CcSEcCtD
Valproic Acid—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000393	0.00119	CcSEcCtD
Valproic Acid—Headache—Teniposide—lymphatic system cancer	0.000393	0.00119	CcSEcCtD
Valproic Acid—Pruritus—Fludarabine—lymphatic system cancer	0.00039	0.00118	CcSEcCtD
Valproic Acid—Back pain—Mitoxantrone—lymphatic system cancer	0.000389	0.00118	CcSEcCtD
Valproic Acid—Leukopenia—Carmustine—lymphatic system cancer	0.000387	0.00117	CcSEcCtD
Valproic Acid—Anorexia—Bleomycin—lymphatic system cancer	0.000385	0.00117	CcSEcCtD
Valproic Acid—Anaemia—Vincristine—lymphatic system cancer	0.000381	0.00116	CcSEcCtD
Valproic Acid—Agitation—Vincristine—lymphatic system cancer	0.000379	0.00115	CcSEcCtD
Valproic Acid—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000379	0.00115	CcSEcCtD
Valproic Acid—Polyuria—Methotrexate—lymphatic system cancer	0.000379	0.00115	CcSEcCtD
Valproic Acid—Photosensitivity—Methotrexate—lymphatic system cancer	0.000379	0.00115	CcSEcCtD
Valproic Acid—Hypotension—Bleomycin—lymphatic system cancer	0.000378	0.00115	CcSEcCtD
Valproic Acid—Diarrhoea—Fludarabine—lymphatic system cancer	0.000377	0.00114	CcSEcCtD
Valproic Acid—Hypertension—Carmustine—lymphatic system cancer	0.000373	0.00113	CcSEcCtD
Valproic Acid—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000373	0.00113	CcSEcCtD
Valproic Acid—Nausea—Teniposide—lymphatic system cancer	0.000372	0.00113	CcSEcCtD
Valproic Acid—Anaemia—Mitoxantrone—lymphatic system cancer	0.000371	0.00113	CcSEcCtD
Valproic Acid—Vertigo—Vincristine—lymphatic system cancer	0.000371	0.00112	CcSEcCtD
Valproic Acid—Hepatic failure—Methotrexate—lymphatic system cancer	0.00037	0.00112	CcSEcCtD
Valproic Acid—Leukopenia—Vincristine—lymphatic system cancer	0.000369	0.00112	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000368	0.00112	CcSEcCtD
Valproic Acid—Myalgia—Carmustine—lymphatic system cancer	0.000368	0.00112	CcSEcCtD
Valproic Acid—Chest pain—Carmustine—lymphatic system cancer	0.000368	0.00112	CcSEcCtD
Valproic Acid—Anxiety—Carmustine—lymphatic system cancer	0.000367	0.00111	CcSEcCtD
Valproic Acid—Paraesthesia—Bleomycin—lymphatic system cancer	0.000363	0.0011	CcSEcCtD
Valproic Acid—Malaise—Mitoxantrone—lymphatic system cancer	0.000362	0.0011	CcSEcCtD
Valproic Acid—Dyspnoea—Bleomycin—lymphatic system cancer	0.00036	0.00109	CcSEcCtD
Valproic Acid—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00036	0.00109	CcSEcCtD
Valproic Acid—Hypertension—Vincristine—lymphatic system cancer	0.000356	0.00108	CcSEcCtD
Valproic Acid—Confusional state—Carmustine—lymphatic system cancer	0.000356	0.00108	CcSEcCtD
Valproic Acid—Oedema—Carmustine—lymphatic system cancer	0.000353	0.00107	CcSEcCtD
Valproic Acid—Decreased appetite—Bleomycin—lymphatic system cancer	0.000351	0.00107	CcSEcCtD
Valproic Acid—Myalgia—Vincristine—lymphatic system cancer	0.000351	0.00107	CcSEcCtD
Valproic Acid—Cough—Mitoxantrone—lymphatic system cancer	0.000351	0.00106	CcSEcCtD
Valproic Acid—Infection—Carmustine—lymphatic system cancer	0.00035	0.00106	CcSEcCtD
Valproic Acid—Vomiting—Fludarabine—lymphatic system cancer	0.00035	0.00106	CcSEcCtD
Valproic Acid—Rash—Fludarabine—lymphatic system cancer	0.000347	0.00105	CcSEcCtD
Valproic Acid—Dermatitis—Fludarabine—lymphatic system cancer	0.000347	0.00105	CcSEcCtD
Valproic Acid—Hypertension—Mitoxantrone—lymphatic system cancer	0.000347	0.00105	CcSEcCtD
Valproic Acid—Pain—Bleomycin—lymphatic system cancer	0.000346	0.00105	CcSEcCtD
Valproic Acid—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000345	0.00105	CcSEcCtD
Valproic Acid—Headache—Fludarabine—lymphatic system cancer	0.000345	0.00105	CcSEcCtD
Valproic Acid—Tachycardia—Carmustine—lymphatic system cancer	0.000344	0.00104	CcSEcCtD
Valproic Acid—Chest pain—Mitoxantrone—lymphatic system cancer	0.000342	0.00104	CcSEcCtD
Valproic Acid—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000342	0.00104	CcSEcCtD
Valproic Acid—Myalgia—Mitoxantrone—lymphatic system cancer	0.000342	0.00104	CcSEcCtD
Valproic Acid—Anxiety—Mitoxantrone—lymphatic system cancer	0.000341	0.00103	CcSEcCtD
Valproic Acid—Lethargy—Methotrexate—lymphatic system cancer	0.000339	0.00103	CcSEcCtD
Valproic Acid—Discomfort—Mitoxantrone—lymphatic system cancer	0.000338	0.00103	CcSEcCtD
Valproic Acid—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000337	0.00102	CcSEcCtD
Valproic Acid—Oedema—Vincristine—lymphatic system cancer	0.000337	0.00102	CcSEcCtD
Valproic Acid—Anorexia—Carmustine—lymphatic system cancer	0.000336	0.00102	CcSEcCtD
Valproic Acid—Infection—Vincristine—lymphatic system cancer	0.000335	0.00101	CcSEcCtD
Valproic Acid—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000333	0.00101	CcSEcCtD
Valproic Acid—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000332	0.00101	CcSEcCtD
Valproic Acid—Confusional state—Mitoxantrone—lymphatic system cancer	0.000331	0.001	CcSEcCtD
Valproic Acid—Nervous system disorder—Vincristine—lymphatic system cancer	0.00033	0.001	CcSEcCtD
Valproic Acid—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00033	0.001	CcSEcCtD
Valproic Acid—Hypotension—Carmustine—lymphatic system cancer	0.00033	0.001	CcSEcCtD
Valproic Acid—Oedema—Mitoxantrone—lymphatic system cancer	0.000328	0.000995	CcSEcCtD
Valproic Acid—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000328	0.000995	CcSEcCtD
Valproic Acid—Nausea—Fludarabine—lymphatic system cancer	0.000327	0.000993	CcSEcCtD
Valproic Acid—Infection—Mitoxantrone—lymphatic system cancer	0.000326	0.000988	CcSEcCtD
Valproic Acid—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000325	0.000988	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000321	0.000975	CcSEcCtD
Valproic Acid—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000321	0.000974	CcSEcCtD
Valproic Acid—Urticaria—Bleomycin—lymphatic system cancer	0.000321	0.000974	CcSEcCtD
Valproic Acid—Anorexia—Vincristine—lymphatic system cancer	0.000321	0.000974	CcSEcCtD
Valproic Acid—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00032	0.000971	CcSEcCtD
Valproic Acid—Body temperature increased—Bleomycin—lymphatic system cancer	0.000319	0.000969	CcSEcCtD
Valproic Acid—Insomnia—Carmustine—lymphatic system cancer	0.000319	0.000968	CcSEcCtD
Valproic Acid—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000319	0.000966	CcSEcCtD
Valproic Acid—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000317	0.000962	CcSEcCtD
Valproic Acid—Paraesthesia—Carmustine—lymphatic system cancer	0.000317	0.000961	CcSEcCtD
Valproic Acid—Mood swings—Methotrexate—lymphatic system cancer	0.000315	0.000955	CcSEcCtD
Valproic Acid—Hypotension—Vincristine—lymphatic system cancer	0.000315	0.000955	CcSEcCtD
Valproic Acid—Dyspnoea—Carmustine—lymphatic system cancer	0.000314	0.000954	CcSEcCtD
Valproic Acid—Somnolence—Carmustine—lymphatic system cancer	0.000314	0.000951	CcSEcCtD
Valproic Acid—Anorexia—Mitoxantrone—lymphatic system cancer	0.000313	0.000948	CcSEcCtD
Valproic Acid—Ataxia—Methotrexate—lymphatic system cancer	0.000313	0.000948	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000307	0.000931	CcSEcCtD
Valproic Acid—Decreased appetite—Carmustine—lymphatic system cancer	0.000307	0.00093	CcSEcCtD
Valproic Acid—Hypotension—Mitoxantrone—lymphatic system cancer	0.000306	0.00093	CcSEcCtD
Valproic Acid—Insomnia—Vincristine—lymphatic system cancer	0.000305	0.000924	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000305	0.000924	CcSEcCtD
Valproic Acid—Paraesthesia—Vincristine—lymphatic system cancer	0.000302	0.000917	CcSEcCtD
Valproic Acid—Constipation—Carmustine—lymphatic system cancer	0.000302	0.000915	CcSEcCtD
Valproic Acid—Pain—Carmustine—lymphatic system cancer	0.000302	0.000915	CcSEcCtD
Valproic Acid—Breast disorder—Methotrexate—lymphatic system cancer	0.0003	0.000911	CcSEcCtD
Valproic Acid—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000299	0.000908	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000299	0.000906	CcSEcCtD
Valproic Acid—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000298	0.000903	CcSEcCtD
Valproic Acid—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000294	0.000893	CcSEcCtD
Valproic Acid—Decreased appetite—Vincristine—lymphatic system cancer	0.000293	0.000888	CcSEcCtD
Valproic Acid—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000292	0.000887	CcSEcCtD
Valproic Acid—Somnolence—Mitoxantrone—lymphatic system cancer	0.000292	0.000884	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000291	0.000882	CcSEcCtD
Valproic Acid—Feeling abnormal—Carmustine—lymphatic system cancer	0.000291	0.000882	CcSEcCtD
Valproic Acid—Fatigue—Vincristine—lymphatic system cancer	0.00029	0.000881	CcSEcCtD
Valproic Acid—Asthenia—Bleomycin—lymphatic system cancer	0.00029	0.00088	CcSEcCtD
Valproic Acid—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000289	0.000876	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000288	0.000875	CcSEcCtD
Valproic Acid—Pain—Vincristine—lymphatic system cancer	0.000288	0.000874	CcSEcCtD
Valproic Acid—Constipation—Vincristine—lymphatic system cancer	0.000288	0.000874	CcSEcCtD
Valproic Acid—Pruritus—Bleomycin—lymphatic system cancer	0.000286	0.000867	CcSEcCtD
Valproic Acid—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000285	0.000865	CcSEcCtD
Valproic Acid—Eosinophilia—Methotrexate—lymphatic system cancer	0.000284	0.000863	CcSEcCtD
Valproic Acid—Fatigue—Mitoxantrone—lymphatic system cancer	0.000283	0.000858	CcSEcCtD
Valproic Acid—Pancreatitis—Methotrexate—lymphatic system cancer	0.000282	0.000855	CcSEcCtD
Valproic Acid—Constipation—Mitoxantrone—lymphatic system cancer	0.00028	0.000851	CcSEcCtD
Valproic Acid—Pain—Mitoxantrone—lymphatic system cancer	0.00028	0.000851	CcSEcCtD
Valproic Acid—Body temperature increased—Carmustine—lymphatic system cancer	0.000279	0.000846	CcSEcCtD
Valproic Acid—Abdominal pain—Carmustine—lymphatic system cancer	0.000279	0.000846	CcSEcCtD
Valproic Acid—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000275	0.000836	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000275	0.000835	CcSEcCtD
Valproic Acid—Pancytopenia—Methotrexate—lymphatic system cancer	0.000273	0.000828	CcSEcCtD
Valproic Acid—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00027	0.00082	CcSEcCtD
Valproic Acid—Dysuria—Methotrexate—lymphatic system cancer	0.000269	0.000815	CcSEcCtD
Valproic Acid—Neutropenia—Methotrexate—lymphatic system cancer	0.000269	0.000815	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000268	0.000813	CcSEcCtD
Valproic Acid—Body temperature increased—Vincristine—lymphatic system cancer	0.000266	0.000808	CcSEcCtD
Valproic Acid—Abdominal pain—Vincristine—lymphatic system cancer	0.000266	0.000808	CcSEcCtD
Valproic Acid—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000262	0.000796	CcSEcCtD
Valproic Acid—Urticaria—Mitoxantrone—lymphatic system cancer	0.00026	0.00079	CcSEcCtD
Valproic Acid—Hypersensitivity—Carmustine—lymphatic system cancer	0.00026	0.000788	CcSEcCtD
Valproic Acid—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000259	0.000786	CcSEcCtD
Valproic Acid—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000259	0.000786	CcSEcCtD
Valproic Acid—Pneumonia—Methotrexate—lymphatic system cancer	0.000258	0.000782	CcSEcCtD
Valproic Acid—Vomiting—Bleomycin—lymphatic system cancer	0.000257	0.000779	CcSEcCtD
Valproic Acid—Drowsiness—Methotrexate—lymphatic system cancer	0.000256	0.000777	CcSEcCtD
Valproic Acid—Depression—Methotrexate—lymphatic system cancer	0.000255	0.000775	CcSEcCtD
Valproic Acid—Rash—Bleomycin—lymphatic system cancer	0.000255	0.000773	CcSEcCtD
Valproic Acid—Dermatitis—Bleomycin—lymphatic system cancer	0.000255	0.000772	CcSEcCtD
Valproic Acid—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000254	0.00077	CcSEcCtD
Valproic Acid—Asthenia—Carmustine—lymphatic system cancer	0.000253	0.000768	CcSEcCtD
Valproic Acid—Stomatitis—Methotrexate—lymphatic system cancer	0.00025	0.000758	CcSEcCtD
Valproic Acid—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000249	0.000755	CcSEcCtD
Valproic Acid—Hypersensitivity—Vincristine—lymphatic system cancer	0.000248	0.000753	CcSEcCtD
Valproic Acid—Sweating—Methotrexate—lymphatic system cancer	0.000246	0.000745	CcSEcCtD
Valproic Acid—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000242	0.000735	CcSEcCtD
Valproic Acid—Epistaxis—Methotrexate—lymphatic system cancer	0.000242	0.000733	CcSEcCtD
Valproic Acid—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000242	0.000733	CcSEcCtD
Valproic Acid—Asthenia—Vincristine—lymphatic system cancer	0.000242	0.000733	CcSEcCtD
Valproic Acid—Diarrhoea—Carmustine—lymphatic system cancer	0.000241	0.000732	CcSEcCtD
Valproic Acid—Nausea—Bleomycin—lymphatic system cancer	0.00024	0.000728	CcSEcCtD
Valproic Acid—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000239	0.000725	CcSEcCtD
Valproic Acid—Asthenia—Mitoxantrone—lymphatic system cancer	0.000235	0.000714	CcSEcCtD
Valproic Acid—Dizziness—Carmustine—lymphatic system cancer	0.000233	0.000708	CcSEcCtD
Valproic Acid—Haemoglobin—Methotrexate—lymphatic system cancer	0.000231	0.000701	CcSEcCtD
Valproic Acid—Diarrhoea—Vincristine—lymphatic system cancer	0.00023	0.000699	CcSEcCtD
Valproic Acid—Haemorrhage—Methotrexate—lymphatic system cancer	0.00023	0.000698	CcSEcCtD
Valproic Acid—Pharyngitis—Methotrexate—lymphatic system cancer	0.000228	0.000692	CcSEcCtD
Valproic Acid—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000227	0.000689	CcSEcCtD
Valproic Acid—Urethral disorder—Methotrexate—lymphatic system cancer	0.000225	0.000684	CcSEcCtD
Valproic Acid—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000224	0.000681	CcSEcCtD
Valproic Acid—Vomiting—Carmustine—lymphatic system cancer	0.000224	0.00068	CcSEcCtD
Valproic Acid—Dizziness—Vincristine—lymphatic system cancer	0.000223	0.000675	CcSEcCtD
Valproic Acid—Rash—Carmustine—lymphatic system cancer	0.000222	0.000675	CcSEcCtD
Valproic Acid—Dermatitis—Carmustine—lymphatic system cancer	0.000222	0.000674	CcSEcCtD
Valproic Acid—Visual impairment—Methotrexate—lymphatic system cancer	0.000222	0.000672	CcSEcCtD
Valproic Acid—Headache—Carmustine—lymphatic system cancer	0.000221	0.00067	CcSEcCtD
Valproic Acid—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000217	0.00066	CcSEcCtD
Valproic Acid—Eye disorder—Methotrexate—lymphatic system cancer	0.000215	0.000652	CcSEcCtD
Valproic Acid—Tinnitus—Methotrexate—lymphatic system cancer	0.000214	0.00065	CcSEcCtD
Valproic Acid—Vomiting—Vincristine—lymphatic system cancer	0.000214	0.000649	CcSEcCtD
Valproic Acid—Rash—Vincristine—lymphatic system cancer	0.000212	0.000644	CcSEcCtD
Valproic Acid—Dermatitis—Vincristine—lymphatic system cancer	0.000212	0.000643	CcSEcCtD
Valproic Acid—Headache—Vincristine—lymphatic system cancer	0.000211	0.00064	CcSEcCtD
Valproic Acid—Nausea—Carmustine—lymphatic system cancer	0.00021	0.000636	CcSEcCtD
Valproic Acid—Angiopathy—Methotrexate—lymphatic system cancer	0.000209	0.000633	CcSEcCtD
Valproic Acid—Vomiting—Mitoxantrone—lymphatic system cancer	0.000208	0.000633	CcSEcCtD
Valproic Acid—Immune system disorder—Methotrexate—lymphatic system cancer	0.000208	0.00063	CcSEcCtD
Valproic Acid—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000207	0.000629	CcSEcCtD
Valproic Acid—Rash—Mitoxantrone—lymphatic system cancer	0.000207	0.000627	CcSEcCtD
Valproic Acid—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000207	0.000627	CcSEcCtD
Valproic Acid—Chills—Methotrexate—lymphatic system cancer	0.000206	0.000626	CcSEcCtD
Valproic Acid—Headache—Mitoxantrone—lymphatic system cancer	0.000205	0.000623	CcSEcCtD
Valproic Acid—Alopecia—Methotrexate—lymphatic system cancer	0.000203	0.000616	CcSEcCtD
Valproic Acid—Mental disorder—Methotrexate—lymphatic system cancer	0.000201	0.000611	CcSEcCtD
Valproic Acid—Malnutrition—Methotrexate—lymphatic system cancer	0.0002	0.000607	CcSEcCtD
Valproic Acid—Nausea—Vincristine—lymphatic system cancer	0.0002	0.000607	CcSEcCtD
Valproic Acid—Dysgeusia—Methotrexate—lymphatic system cancer	0.000196	0.000595	CcSEcCtD
Valproic Acid—Nausea—Mitoxantrone—lymphatic system cancer	0.000195	0.000591	CcSEcCtD
Valproic Acid—Back pain—Methotrexate—lymphatic system cancer	0.000194	0.000587	CcSEcCtD
Valproic Acid—Vision blurred—Methotrexate—lymphatic system cancer	0.000189	0.000572	CcSEcCtD
Valproic Acid—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000186	0.000563	CcSEcCtD
Valproic Acid—Anaemia—Methotrexate—lymphatic system cancer	0.000185	0.000561	CcSEcCtD
Valproic Acid—Malaise—Methotrexate—lymphatic system cancer	0.000181	0.000548	CcSEcCtD
Valproic Acid—Vertigo—Methotrexate—lymphatic system cancer	0.00018	0.000546	CcSEcCtD
Valproic Acid—Leukopenia—Methotrexate—lymphatic system cancer	0.000179	0.000544	CcSEcCtD
Valproic Acid—Cough—Methotrexate—lymphatic system cancer	0.000175	0.00053	CcSEcCtD
Valproic Acid—Arthralgia—Methotrexate—lymphatic system cancer	0.00017	0.000517	CcSEcCtD
Valproic Acid—Myalgia—Methotrexate—lymphatic system cancer	0.00017	0.000517	CcSEcCtD
Valproic Acid—Chest pain—Methotrexate—lymphatic system cancer	0.00017	0.000517	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000169	0.000513	CcSEcCtD
Valproic Acid—Discomfort—Methotrexate—lymphatic system cancer	0.000168	0.000511	CcSEcCtD
Valproic Acid—Confusional state—Methotrexate—lymphatic system cancer	0.000165	0.0005	CcSEcCtD
Valproic Acid—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000163	0.000496	CcSEcCtD
Valproic Acid—Infection—Methotrexate—lymphatic system cancer	0.000162	0.000492	CcSEcCtD
Valproic Acid—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00016	0.000486	CcSEcCtD
Valproic Acid—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00016	0.000485	CcSEcCtD
Valproic Acid—Skin disorder—Methotrexate—lymphatic system cancer	0.000159	0.000481	CcSEcCtD
Valproic Acid—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000158	0.000479	CcSEcCtD
Valproic Acid—Anorexia—Methotrexate—lymphatic system cancer	0.000156	0.000472	CcSEcCtD
Valproic Acid—Hypotension—Methotrexate—lymphatic system cancer	0.000153	0.000463	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000149	0.000452	CcSEcCtD
Valproic Acid—Insomnia—Methotrexate—lymphatic system cancer	0.000148	0.000448	CcSEcCtD
Valproic Acid—Paraesthesia—Methotrexate—lymphatic system cancer	0.000147	0.000445	CcSEcCtD
Valproic Acid—Dyspnoea—Methotrexate—lymphatic system cancer	0.000146	0.000442	CcSEcCtD
Valproic Acid—Somnolence—Methotrexate—lymphatic system cancer	0.000145	0.000441	CcSEcCtD
Valproic Acid—Dyspepsia—Methotrexate—lymphatic system cancer	0.000144	0.000436	CcSEcCtD
Valproic Acid—Decreased appetite—Methotrexate—lymphatic system cancer	0.000142	0.000431	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000141	0.000428	CcSEcCtD
Valproic Acid—Fatigue—Methotrexate—lymphatic system cancer	0.000141	0.000427	CcSEcCtD
Valproic Acid—Pain—Methotrexate—lymphatic system cancer	0.00014	0.000424	CcSEcCtD
Valproic Acid—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000135	0.000408	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000134	0.000405	CcSEcCtD
Valproic Acid—Urticaria—Methotrexate—lymphatic system cancer	0.00013	0.000394	CcSEcCtD
Valproic Acid—Abdominal pain—Methotrexate—lymphatic system cancer	0.000129	0.000392	CcSEcCtD
Valproic Acid—Body temperature increased—Methotrexate—lymphatic system cancer	0.000129	0.000392	CcSEcCtD
Valproic Acid—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00012	0.000365	CcSEcCtD
Valproic Acid—Asthenia—Methotrexate—lymphatic system cancer	0.000117	0.000356	CcSEcCtD
Valproic Acid—Pruritus—Methotrexate—lymphatic system cancer	0.000116	0.000351	CcSEcCtD
Valproic Acid—Diarrhoea—Methotrexate—lymphatic system cancer	0.000112	0.000339	CcSEcCtD
Valproic Acid—Dizziness—Methotrexate—lymphatic system cancer	0.000108	0.000328	CcSEcCtD
Valproic Acid—Vomiting—Methotrexate—lymphatic system cancer	0.000104	0.000315	CcSEcCtD
Valproic Acid—Rash—Methotrexate—lymphatic system cancer	0.000103	0.000313	CcSEcCtD
Valproic Acid—Dermatitis—Methotrexate—lymphatic system cancer	0.000103	0.000312	CcSEcCtD
Valproic Acid—Headache—Methotrexate—lymphatic system cancer	0.000102	0.000311	CcSEcCtD
Valproic Acid—Nausea—Methotrexate—lymphatic system cancer	9.7e-05	0.000294	CcSEcCtD
